Market Cap
$497.1M
RGNX
REGENXBIO Inc.
$7.43 ▲ +0.13%
Prev close $7.42Market cap$497.1M
ConsensusStrong Buy
12-mo target$23.73 (+219.3%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10)23 New Institutional Positions14 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on RGNX right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (84%)
Inst. Holders
50 funds
Inst. Value
$403.3M
Inst. Activity
23 buys / 14 sells
Insider Activity
$949.4K buy / $940.0K sell
Insider Net $
$9.4K
SEC Reports
9
Press Releases
1
Price chart 30d -19.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 short_volume
Short Volume: RGNX — 56.7% short (0.3M / 0.6M)
Short: 329,357 | Exempt: 200 | TRF Vol: 580,886 | Short Ratio: 56.7% | Off-exchange volume (dark poo
Sep 1, 2026 Insider
Malzahn Craig surrendered for taxes 234 shares
Chief Technology Officer @ $9.32 ($2.2K)
Sep 1, 2026 Insider
Aug 27, 2026 SEC Chan Mitchell surrendered for taxes 4,902 shares
Chief Financial Officer @ $9.32 ($45.7K)
Director Gregory Ciongoli made a $450K open-market purchase of RGNX shares at $9.14 on August 26, adding to a $500K purc
INSIDER-BUY — Impact 5/10
Aug 27, 2026 Insider
Aug 25, 2026 SEC Ciongoli Gregory Austin bought 53,407 shares
Director @ $9.36 ($499.7K)
REGENXBIO appointed Greg Ciongoli as a Class II director and accepted the resignations of Jean Bennett and Jerry Karabel
8-K — Impact 3/10
REGENXBIO reported Q2 2026 GAAP net income of $22.7M ($0.43 EPS) vs consensus of -$0.11, driven by a $100M AbbVie milest
8-K — Impact 7/10
REGENXBIO priced a $100M underwritten public offering of 10M shares at $9.00/share plus 1.1M pre-funded warrants, repres
Impact 7/10
Analyst ratings buy % -5.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
84% rate it Buy or better · 19 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 25, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Aug 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 7, 2026 | Barclays | DOWNGRADE | Equal-Weight | 54% |
| Jun 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 22, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Jun 22, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
| Jun 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 15, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
| May 15, 2026 | Barclays | MAINTAIN | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 10 | 3 | 0 | 0 | 84% | |
| Aug 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Jul 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Jun 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| May 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Feb 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% |
Price targets
Where 11 covering analysts think RGNX trades over the next 12 months.
$23.73 +219.3% upside Strong Buy
Current$7.43 Low$10.00 Median$19.00 High$50.00 11 analysts
$10.00$50.00
Analyst rating Buy· 1.6/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 3 bullish, 1 bearish, 2 mixed, 3 neutral · avg impact 5.1/10.Plus 1 press releases.
BULLISHINSIDER-BUY5/10
Director Gregory Ciongoli made a $450K open-market purchase of RGNX shares at $9.14 on August 26, ad
Aug 27, 2026
NEUTRAL8-K3/10
REGENXBIO appointed Greg Ciongoli as a Class II director and accepted the resignations of Jean Benne
Aug 25, 2026
BULLISH8-K7/10
REGENXBIO reported Q2 2026 GAAP net income of $22.7M ($0.43 EPS) vs consensus of -$0.11, driven by a
Aug 6, 2026
NEUTRALPRESS-RELEASE2/10
REGENXBIO issued a press release announcing a conference call on August 6, 2026, to discuss Q2 2026
Aug 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
short_volume
Short Volume: RGNX — 56.7% short (0.3M / 0.6M)
Short: 329,357 | Exempt: 200 | TRF Vol: 580,886 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
short_volume
Short Volume: RGNX — 61.3% short (0.4M / 0.7M)
Short: 412,872 | Exempt: 706 | TRF Vol: 673,310 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_volume
Short Volume: RGNX — 64.3% short (0.3M / 0.5M)
Short: 331,804 | Exempt: 7,900 | TRF Vol: 515,689 | Short Ratio: 64.3% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
other
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
Aug 25, 2026
other
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.27 | $-1.63–$-0.89 | -5.7% | +0.0% | 4↑ 2↓ | $0.0B | 8 |
| Next Q | $-0.96 | $-1.90–$1.15 | 25.8% | +0.0% | 4↑ 3↓ | $0.0B | 8 |
| Current FY | $-3.52 | $-4.86–$-1.03 | 6.4% | +0.0% | 4↑ 3↓ | $0.2B | 8 |
| Next FY | $-3.00 | $-4.81–$0.13 | 14.6% | +0.0% | 5↑ 2↓ | $0.2B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.268 | — |
| 7d ago | $-1.268 | — |
| 30d ago | $-1.268 | — |
| 60d ago | $-0.967 | -0.301 |
| 90d ago | $-1.224 | -0.044 |
Institutional ownership
Which big funds own RGNX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $403.3M total value (33,694,547 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, JPMORGAN. Net buying activity: 23 institutions added/increased vs 14 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 6,397,440 | $76.6M | 19.0% | — |
| STATE STREET CORP | 2,971,173 | $35.6M | 8.8% | — |
| JPMORGAN CHASE & CO | 2,214,169 | $26.2M | 6.5% | TRIM -36.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,107,557 | $25.2M | 6.3% | — |
| MORGAN STANLEY | 1,953,237 | $23.4M | 5.8% | — |
| GOLDMAN SACHS GROUP INC | 1,421,453 | $17.0M | 4.2% | — |
| AQR CAPITAL MANAGEMENT LLC | 1,378,358 | $16.5M | 4.1% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,355,554 | $16.2M | 4.0% | ADD +33.0% |
| MARSHALL WACE, LLP | 1,284,950 | $15.4M | 3.8% | NEW |
| GEODE CAPITAL MANAGEMENT, LLC | 1,241,296 | $14.9M | 3.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | TRIM | 3,483,800 | 2,214,169 | -36.4% | $26.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 1,018,901 | 1,355,554 | +33.0% | $16.2M |
| MARSHALL WACE, LLP | NEW | — | 1,284,950 | — | $15.4M |
| Nuveen, LLC | ADD | 582,016 | 740,026 | +27.1% | $8.9M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 1,010,381 | 731,586 | -27.6% | $8.8M |
| D. E. Shaw & Co., Inc. | DOUBLED | 286,001 | 712,814 | +149.2% | $8.5M |
| STIFEL FINANCIAL CORP | ADD | 392,769 | 560,727 | +42.8% | $6.7M |
| BANK OF AMERICA CORP /DE/ | ADD | 324,860 | 518,545 | +59.6% | $6.2M |
| MILLENNIUM MANAGEMENT LLC | ADD | 285,174 | 480,762 | +68.6% | $5.8M |
| Quantinno Capital Management LP | DOUBLED | 43,951 | 300,127 | +582.9% | $3.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
15 insiders, 38 transactions. Net $9.4K — $949.4K bought, $940.0K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Malzahn Craig | Chief Technology Officer | TAX W/H | 234 | $9.32 | $2.2K |
| Sep 1, 2026 | Chan Mitchell | Chief Financial Officer | TAX W/H | 4,902 | $9.32 | $45.7K |
| Aug 27, 2026 | Ciongoli Gregory Austin | Director | BUY | 53,407 | $9.36 | $499.7K |
| Aug 26, 2026 | Ciongoli Gregory Austin | Director | BUY | 49,196 | $9.14 | $449.7K |
| Aug 25, 2026 | Ciongoli Gregory Austin | Director | AWARD | 15,432 | — | — |
| Aug 25, 2026 | Ciongoli Gregory Austin | Director | AWARD | 69,609 | — | — |
| Aug 1, 2026 | Christmas Patrick J. | Chief Strategy & Legal Officer | TAX W/H | 4,699 | $9.69 | $45.5K |
| Aug 1, 2026 | PAKOLA STEVE | Chief Medical Officer | TAX W/H | 7,468 | $9.69 | $72.4K |
| Jul 2, 2026 | PAKOLA STEVE | Chief Medical Officer | SELL | 2,161 | $13.64 | $29.5K |
| Jul 2, 2026 | PAKOLA STEVE | Chief Medical Officer | EXERCISE | 2,161 | $7.86 | $17.0K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for RGNX.
Shares short
7,927,603
Settlement Sep 15, 2026
Change vs prior
+5.7%
Semi-monthly cycle
Days to cover
7.7
At avg daily volume
Of shares outstanding
≈12.0%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Aug 24, 2026 | T1 | News Pending | Not resumed |
| Aug 24, 2026 | T2 | News Released | Not resumed |
| Aug 24, 2026 | T3 | Resumption Scheduled | Resumed |
All RGNX filing & press-release reports (10)
- INSIDER-BUY reportAug 27, 2026
- 8-K reportAug 25, 2026
- 8-K reportAug 6, 2026
- PRESS-RELEASE reportAug 3, 2026
- 8-K reportJul 20, 2026
- PRESS-RELEASE reportJul 17, 2026
- 8-K reportJul 3, 2026
- 8-K reportJun 3, 2026
- 8-K reportMay 14, 2026
- 8-K reportMar 5, 2026